PI
RARE icon

PEAK6 Investments’s Ultragenyx Pharmaceutical RARE Stock Holding History

PEAK6 Investments’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,999
Closed -$277K – 4474
2023
Q2 		$277K Buy
+5,999
New +$278K ﹤0.01% 2660
2022
Q3 		– Sell
-5,999
Closed -$277K – 5905
2022
Q2 		$277K Buy
+5,999
New +$369K ﹤0.01% 4455

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

PEAK6 Investments's RARE Position: Q3 2023 in Review

PEAK6 Investments sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2023, closing a stake of 5,999 shares — an estimated $277K sold.

PEAK6 Investments first reported a position in RARE in Q2 2022 and held it in 2 quarters. The position peaked at $277K in Q2 2023. 219 funds tracked by Wall St. Rank hold RARE as of Q3 2023.

  • PEAK6 Investments reported no remaining Ultragenyx Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • PEAK6 Investments sold 5,999 Ultragenyx Pharmaceutical shares in Q3 2023, an estimated $277K.
  • PEAK6 Investments first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 2 quarters.
  • PEAK6 Investments's Ultragenyx Pharmaceutical position peaked at $277K in Q2 2023.
  • 219 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2023.

Based on PEAK6 Investments's 13F filing for Q3 2023, filed 13 Nov 2023.